Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsJohad Khoury
Assistant Professor AdjunctAbout
Research
Publications
2026
A109-23 The Profibrotic Effect of Mechanical Force on Airway Basal Cells in Pulmonary Fibrosis
Lin L, Salimi M, Du H, Khoury J, Giuseppe D, Alzate K, Szafron J, Manning E, Kaminski N, Ahangari F. A109-23 The Profibrotic Effect of Mechanical Force on Airway Basal Cells in Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2026, 212: aamag162.2423. DOI: 10.1093/ajrccm/aamag162.2423.Peer-Reviewed Original ResearchAirway basal cellsIdiopathic pulmonary fibrosisPulmonary fibrosisProfibrotic effectsBasal cellsBleomycin-treated miceTGF-b1 expressionIdiopathic pulmonary fibrosis progressionAirway epithelial cellsScarring lung diseaseAir-liquid interfaceDifferentiation stateAnnexin V-FITC/PI stainingGene expressionFibrotic remodelingFibrosis progressionNo significant changesHealthy miceAbnormal responseLung diseaseVentilated lungFibrotic genesAlveolar destructionElevated mechanical stressEpithelial cellsB94-07 Partial Adherence to Biologic Therapies in Severe Asthma: Is It as Good?
Khoury J, Adir Y, Saliba W, Fireman Klein E, Shteinberg M, Humbert M. B94-07 Partial Adherence to Biologic Therapies in Severe Asthma: Is It as Good? American Journal Of Respiratory And Critical Care Medicine 2026, 212: aamag162.504. DOI: 10.1093/ajrccm/aamag162.504.Peer-Reviewed Original ResearchBiologic therapyAdherent patientsSevere asthmaPartial adherencePrednisone doseTreatment failureExacerbation rateMedication switchPopulation-based retrospective cohort studyDupilumab-treated patientsBlood eosinophil countRetrospective cohort studyAdherence to therapyClalit Health ServicesAdherence to treatmentRandomized Controlled TrialsCorticosteroid dependenceCorticosteroid usePrednisone useInitial treatmentAcute exacerbationAdherence groupEosinophil countCohort studyAdequate adherenceERS Congress 2025: highlights from the interstitial lung diseases assembly. The future is ahead
Khoury J, Yüksel A, Bizymi N, Fabozzi A, Garcia-Moyano M, Wijsenbeek M, Kreuter M, Fabbri L. ERS Congress 2025: highlights from the interstitial lung diseases assembly. The future is ahead. ERJ Open Research 2026, 00344-2026. DOI: 10.1183/23120541.00344-2026.Peer-Reviewed Original ResearchThe Interplay of Airway Epithelium and Biomechanical Stress in Pulmonary Fibrosis
Lin L, Khoury J, Zhang G, Szafron J, Manning E, Ahangari F. The Interplay of Airway Epithelium and Biomechanical Stress in Pulmonary Fibrosis. American Journal Of Respiratory Cell And Molecular Biology 2026, aanag066. PMID: 42089315, DOI: 10.1093/ajrcmb/aanag066.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisAirway epitheliumPulmonary fibrosisEpithelial responsesEpithelial cellsResponse of airway epithelial cellsPathogenesis of idiopathic pulmonary fibrosisRegulation of lung functionProgression of idiopathic pulmonary fibrosisAirway epithelial cellsProgression of fibrosisAirway epithelial responsesPro-fibrotic responseIndicators of disease onsetFatal lung diseaseEarly indicatorLung fibrosisAbnormal responseLung diseaseDisease onsetLung functionLung tissueFibrosisAirwayTherapeutic interventionsVascular Endothelial Growth Factor-D Improves Lung Vascular Integrity During Acute Lung Injury
Yoon Y, Sharma L, Tang W, Kirk S, Raredon M, Ahangari F, Khoury J, Qian H, Ke Y, Tulapurkar M, Liu R, Luan Y, Yuan Q, Chen L, Birukov K, Simons M, Wu D, Niklason L, Kaminski N, Yuan Y. Vascular Endothelial Growth Factor-D Improves Lung Vascular Integrity During Acute Lung Injury. Circulation Research 2026, 138: e326094. PMID: 41822962, PMCID: PMC13007730, DOI: 10.1161/circresaha.124.326094.Peer-Reviewed Original ResearchVEGF-DAcute lung injuryBarrier-protective effectsVascular integrityLung injuryLipopolysaccharide-induced acute lung injury modelIntravenous administrationTNF-aParacrine signalingModel of acute lung injuryPulmonary vascular integrityLigand-receptor interactionsImmune cell infiltrationAcute lung injury modelLung vascular integrityVEGFR2-dependent signalingLung injury modelEndothelial barrier integrityEndothelial barrier functionRNA sequencing dataMicrovascular endothelial cellsInhibition of VEGFR2Microvascular nichePharmacological blockadeAssociated with pathwaysEpidermal growth factor receptor regulates Beclin-1 in hyperoxic acute lung injury
Harris Z, Korde A, Khoury J, Manning E, Stanley G, Shin Y, Mitchell K, von der Schulenburg A, Sun Y, Hu B, Shin H, Joerns J, Clark B, Placek L, Unutmaz D, Moldobaeva A, Sharma L, Sauler M, Rajagopalan G, Zhang X, Wang H, Ghaedi M, Kang M, Koff J. Epidermal growth factor receptor regulates Beclin-1 in hyperoxic acute lung injury. BMJ Open Respiratory Research 2026, 13: e003323. PMID: 41592865, PMCID: PMC12853440, DOI: 10.1136/bmjresp-2025-003323.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorAcute lung injuryHyperoxic ALIHyperoxic acute lung injuryGrowth factor receptorIn vivo effectsLung injuryOxidant-mediated acute lung injuryFactor receptorIntensive care unit mortalityExposure to high oxygenAlveolar type II cellsDelivery of supplemental oxygenPulmonary cell deathLife-saving therapyPluripotent stem cellsType II cellsNormoxia controlSupplemental oxygenUnit mortalityAlveolar epitheliumBeclin-1Cell death pathwaysStem cellsTherapeutic potentialPulmonary hypertension associated with nonparenchymal restrictive lung diseases
Jutant E, Humbert M, Montani D, Khoury J, Adir Y. Pulmonary hypertension associated with nonparenchymal restrictive lung diseases. European Respiratory Review 2026, 35: 250187. PMID: 41813013, PMCID: PMC12976881, DOI: 10.1183/16000617.0187-2025.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPulmonary hypertensionRestrictive lung diseaseLung diseaseAssociated with chronic lung diseaseGroup 3 PHPulmonary arterial hypertensionCombined pulmonary fibrosisInterstitial lung diseaseChronic lung diseaseHypoventilation syndromeArterial hypertensionVentilatory disordersClinical manifestationsPulmonary fibrosisMechanisms of PHPathophysiological mechanismsDisease subgroupsDiseaseHypertensionLungSubgroupsPneumonectomyHypoventilationFibrosisPatients
2025
Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor–CD74 signaling
Kim S, Nouws J, Ruwisch J, Woodard G, Cooley J, Khoury J, Sun H, Doherty E, Piecychna M, Manning E, Kang M, Bruscia E, Wei H, Zhang Y, Yarovinsky T, Hwa J, Zacharias W, Ingram J, Lee C, Elias J, Kaminski N, Redente E, Herzog E, Prasse A, Bucala R, Sauler M. Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor–CD74 signaling. Science Translational Medicine 2025, 17: eadr2277. PMID: 41337540, DOI: 10.1126/scitranslmed.adr2277.Peer-Reviewed Original ResearchMeSH KeywordsAlveolar Epithelial CellsAnimalsAntigens, Differentiation, B-LymphocyteBleomycinDisease Models, AnimalHistocompatibility Antigens Class IIHumansIdiopathic Pulmonary FibrosisIntramolecular OxidoreductasesLungMacrophage Migration-Inhibitory FactorsMacrophagesMaleMiceMice, Inbred C57BLMice, TransgenicProteasome Endopeptidase ComplexProteostasisSignal TransductionUbiquitinConceptsIdiopathic pulmonary fibrosisMacrophage migration inhibitory factorBronchoalveolar lavage fluidPharmacological inhibition of MIFBleomycin-induced lung injury modelMouse modelPharmacological inhibitionC-X3-C motif chemokine receptor 1Human precision-cut lung slicesTransforming growth factor-b1Inhibition of macrophage migration inhibitory factorSignals to macrophagesPrecision-cut lung slicesFibrotic lung diseaseType 2 epithelial cellsAlveolar type 2 epithelial cellsChemokine receptor 1Lung injury modelMigration inhibitory factorMIF-2Study participantsUbiquitin-proteasome systemSpontaneous fibrosisPulmonary fibrosisLavage fluidSeparation of telomere protection from length regulation by two different point mutations at amino acid 492 of RTEL1
Smoom R, May C, Lichtental D, Bar-Ness K, Rangel R, Khoury J, Nachmani D, Avrahami D, Ahangari F, Skordalakes E, Kaminski N, Kaestner K, Tzfati Y. Separation of telomere protection from length regulation by two different point mutations at amino acid 492 of RTEL1. Nucleic Acids Research 2025, 53: gkaf507. PMID: 40530700, PMCID: PMC12203905, DOI: 10.1093/nar/gkaf507.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SubstitutionAnimalsDisease Models, AnimalDNA DamageDNA HelicasesDyskeratosis CongenitaFetal Growth RetardationGrowth DisordersHematopoiesisHumansIntellectual DisabilityLimb Deformities, CongenitalLungMiceMicrocephalyPoint MutationTelomereTelomere HomeostasisX-Linked Intellectual DisabilityConceptsHoyeraal-Hreidarsson syndromeTelomere protectionLength regulationTelomere length regulationTelomere-related diseasesTelomere biology disordersDNA helicaseMouse genomeGenome stabilityMouse modelMouse telomeresAberrant hematopoiesisGenomic instabilityPoint mutationsHouse miceTelomeric DNA damageAnaphase bridgesRTEL1Amino acidsTelomereMechanistic rolesDNA damageMutationsIsoleucine mutationGenomeTicagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety
Bahouth F, Chutko B, Sholy H, Hassanain S, Zaid G, Radzishevsky E, Fahmwai I, Hamoud M, Samnia N, Khoury J, Dobrecky-Mery I. Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety. Medicines 2025, 12: 13. PMID: 40407605, PMCID: PMC12194868, DOI: 10.3390/medicines12020013.Peer-Reviewed Original ResearchAcute coronary syndromeCoronary syndromeAntiplatelet drugsCardiovascular deathComposite endpoint of cardiovascular deathAdmitted with acute coronary syndromeEndpoint of cardiovascular deathTreated with ticagrelorTreated with prasugrelSingle-center studyRetrospective observational studyRecurrent cardiac eventsDual antiplatelet drugsReal-world treatmentPercutaneous coronary interventionBARC classificationSignificant bleedingPrasugrel groupPrimary endpointP2Y12 inhibitorsNo significant differenceACS patientsCardiac eventsComposite endpointPrasugrel